This article is from the source 'bbc' and was first published or seen on . It will not be checked again for changes.
You can find the current article at its original source at http://news.bbc.co.uk/go/rss/-/1/hi/health/6642749.stm
The article has changed 2 times. There is an RSS feed of changes available.
Previous version
1
Next version
Version 0 | Version 1 |
---|---|
Drugs adviser raises charity fear | |
(about 8 hours later) | |
Concerns have been raised about the links between pharmaceutical firms and charity patient groups by the body that advises the NHS on which drugs to use. | |
Sir Michael Rawlins, chairman of the National Institute for Health and Clinical Excellence, said charities had to be wary of pharmaceutical donations. | Sir Michael Rawlins, chairman of the National Institute for Health and Clinical Excellence, said charities had to be wary of pharmaceutical donations. |
And he urged charities to question the cost of drugs more. | And he urged charities to question the cost of drugs more. |
But patient groups said there were strict guidelines covering such donations by the drugs industry. | But patient groups said there were strict guidelines covering such donations by the drugs industry. |
I have yet ever to hear a patient organisation criticise a price of the drug Sir Michael Rawlins, of NICE | I have yet ever to hear a patient organisation criticise a price of the drug Sir Michael Rawlins, of NICE |
Sir Michael said: "Patient organisations need to think very carefully about why pharmaceutical companies are giving them money and they have to make sure they are not beholden to a pharmaceutical company. | Sir Michael said: "Patient organisations need to think very carefully about why pharmaceutical companies are giving them money and they have to make sure they are not beholden to a pharmaceutical company. |
"I have yet ever to hear a patient organisation criticise a price of the drug. | "I have yet ever to hear a patient organisation criticise a price of the drug. |
"When they do that they will come into their own." | "When they do that they will come into their own." |
Sir Michael refused to name individual groups | Sir Michael refused to name individual groups |
The subject of drug firm donations to patients groups and charities is a sensitive issue. | The subject of drug firm donations to patients groups and charities is a sensitive issue. |
Several groups, although not all, accept donations from drug firms. | Several groups, although not all, accept donations from drug firms. |
Most of those that do have codes of conduct setting out what those donations can and cannot be used for - most are restricted to funding education purposes than for campaigning. | Most of those that do have codes of conduct setting out what those donations can and cannot be used for - most are restricted to funding education purposes than for campaigning. |
Treatments | Treatments |
The Alzheimer's Society is involved in legal action along with Eisai and Pfizer against NICE over the decision to restrict the use of Alzheimer's treatments. | The Alzheimer's Society is involved in legal action along with Eisai and Pfizer against NICE over the decision to restrict the use of Alzheimer's treatments. |
The group has accepted money from both companies. | The group has accepted money from both companies. |
But a spokeswoman pointed out that drug firm donations account for less than 1% of its income. | But a spokeswoman pointed out that drug firm donations account for less than 1% of its income. |
She said the society's challenge was being done independently of the drug firms and added donations were never used to fund campaign activity. | She said the society's challenge was being done independently of the drug firms and added donations were never used to fund campaign activity. |
Breast Cancer Care, which pushed for NICE to approve the so-called breast cancer wonder-drug Herceptin, has received money from its maker Roche. | Breast Cancer Care, which pushed for NICE to approve the so-called breast cancer wonder-drug Herceptin, has received money from its maker Roche. |
A spokeswoman said any drug industry donations were always used for "impartial patient information". | A spokeswoman said any drug industry donations were always used for "impartial patient information". |
She added it was important there was a dialogue between patient groups and drug companies and she agreed cost was something that needed to be debated. | She added it was important there was a dialogue between patient groups and drug companies and she agreed cost was something that needed to be debated. |
"The cost of drug is clearly becoming a major factor in the potential for cancer treatment and must be addressed." | "The cost of drug is clearly becoming a major factor in the potential for cancer treatment and must be addressed." |
And the Association of the British Pharmaceutical Industry denied there was anything wrong with such donations. | And the Association of the British Pharmaceutical Industry denied there was anything wrong with such donations. |
"Patient groups and companies have a shared interest. When they work together it is in the patients' interests, usually to do with education programmes or disease awareness. | "Patient groups and companies have a shared interest. When they work together it is in the patients' interests, usually to do with education programmes or disease awareness. |
"Any involvement has to be declared by the company so it is quite transparent." | "Any involvement has to be declared by the company so it is quite transparent." |
Previous version
1
Next version